

Intellectual Property LEGALNEWS

THE SUPREME COURT HOLDS HUMAN GENES ARE UNPATENTABLE


by Joan Ellis, Ph.D., Washington, DC office

In a unanimous decision written by Justice Thomas, the Supreme Court held that naturally-occurring DNA sequences are unpatentable. The Court has long held that certain subject matter is not patent eligible under 35 USC § 101. Patent exempt subject matter includes laws of nature, natural phenomenon, and abstract ideas. In this case, the Court found that human genes are products of nature. The Court further found that cDNA sequences, which are copies of non-intron containing mRNA sequences created in the laboratory, are patent eligible.

The case before the Court involved several patents issued to Myriad Genetics, Inc. ("Myriad") that were directed to two genes known as BRCA1 and BRCA2. Mutations in these genes can increase a woman's risk of developing breast and ovarian cancer. The scientists at Myriad had discovered the genes, determined their nucleotide sequence and their chromosomal location. The Court found that locating and isolating the genes did not make them new compositions of matter. The Court acknowledged that the genes were important and useful, but nevertheless concluded that "Myriad did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes. The location and order of the nucleotides existed in nature before Myriad found them." Thus, the "genes and the information they code are not patent eligible under § 101 simply because they have been isolated from the surrounding genetic material."

The Court found that cDNA sequences stood on a different footing. The Court acknowledged that cDNA contains naturally-occurring coding sequences of DNA known as exons, but observed that it differs in that intervening non-coding sequences are removed by a lab technician. Consequently, the Court held that cDNA is not a product of nature and may be patent eligible.

The Court went to great pains to point out that the decision was limited to the genes themselves. The Court explicitly stated that it was not passing judgment on patent claims directed to methods of isolating or manipulating genes. Although they noted that the isolation methods used by Myriad were "well understood, widely used, and fairly uniform in so far as any scientist engaged in the search for a gene would likely have utilized a similar approach."



July 25, 2013 • Volume 1, Number 4

IP LEGAL NEWS EDITORIAL BOARD

H. Jonathan Redway - Washington, D.C. Office
202.659.6946 • jredway@dickinsonwright.com

Christopher A. Mitchell - Ann Arbor Office
734.623.1906 • cmitchell@dickinsonwright.com

John S. Artz - Troy Office
248.433.7262 • jsartz@dickinsonwright.com

Paul E. Bain - Toronto Office
416-646-8364 • pbain@dickinsonwright.com

Scot L. Claus - Phoenix Office
602.285.5080 • sclaus@dickinsonwright.com

IP WEB SITES OF INTEREST

United States Patent and Trademark Office - www.uspto.gov

Office of Harmonization for the Internal Market -

www.oami.europa.eu

European Patent Office - www.epo.org

Canadian Intellectual Property Office - www.cipo.ic.gc.ca

Japanese Patent Office - www.jpo.go.jp

United States Copyright Office - www.copyright.gov

Google Patents - www.google.com/patents

World Intellectual Property Office - www.wipo.int

Disclaimer: Intellectual Property Legal News is published by Dickinson Wright PLLC to inform our clients and friends of important developments in the field of intellectual property law. The content is informational only and does not constitute legal or professional advice. We encourage you to consult a Dickinson Wright attorney if you have specific questions or concerns relating to any of the topics or any other intellectual property matter.

Of paramount importance is that Court's decision did not encompass patent claims directed to "new applications of knowledge about the BRCA1 and BRCA2 genes" or "scientific alteration of the genetic code." After all, it is the potential use of a DNA sequence that is the *raison d'être* for isolating it in the first instance. The ultimate goal of all DNA research is for the gain, financial or otherwise, that is obtained in developing a new diagnostic assays, gene therapy, therapeutics, herbicide resistance, etc. that use the DNA. The practical application of a DNA sequence has always been where the true value lies.

The *Myriad* decision will have a tremendous impact on the biotechnology industry. Tens of thousands of existing patents having claims that are exclusively directed to DNA sequences and fragments thereof can now be challenged and invalidated. The United States Patent and Trademark Office (USPTO) has already published new

interim guidelines for the patent examiners. Referring to the Supreme Court's decision in *Myriad*, the new guidelines instruct the examiners to "now reject product claims drawn solely to naturally occurring nucleic acids or fragments thereof, whether isolated or not, as being ineligible subject matter under 35 U.S.C. § 101."

In the wake of the *Myriad* decision, biotech companies would be well advised to protect their intellectual property by immediately examining their patent portfolios. Claims in pending patent applications should be amended and/or new claims added that are directed to cDNA sequences and methods of using said sequences. Steps should be taken to safeguard those patents that have already issued from litigation. To that end, companies should consider amending the claims in issued patents by filing a request for reissue or reexamination.

Dickinson Wright Offices

Detroit

500 Woodward Avenue
Suite 4000
Detroit, MI 48226
Phone: 313.223.3500

Toronto

199 Bay Street, Suite 2200
Commerce Court West
Toronto ON M5L 1G4
Phone: 416.77.0101

Saginaw

4800 Fashion Square Boulevard
Suite 300
Saginaw, MI 48604
Phone: 989-791-4646

Columbus

150 E. Gay Street
Suite 2400
Columbus, OH 43215
Phone: 614.744.2570

Washington, D.C.

1875 Eye Street, NW
Suite 1200
Washington, DC 20006
Phone: 202.457.0160

Troy

2600 W. Big Beaver Road
Suite 300
Troy, MI 48084
Phone: 248.433.7200

Las Vegas

7201 West Lake Mead Boulevard
Suite 503
Las Vegas, NV 89128
Phone: 702.541.7888

Ann Arbor

350 S. Main Street
Suite 300
Ann Arbor, MI 48104
Phone: 734-623-7075

Nashville

424 Church Street
Suite 1401
Nashville, TN 37219
Phone: 615.244.6538

Grand Rapids

200 Ottawa Avenue, NW
Suite 1000
Grand Rapids, MI 49503
Phone: 616.458.1300

Phoenix

2901 N. Central Avenue
Suite 200
Phoenix, AZ 85012
Phone: 602-285-5000

Lansing

215 S. Washington Square
Suite 200
Lansing, MI 48933
Phone: 517.371.1730